Platelet function analysis: At the edge of meaning

Julie H. Oestreich; Susan S. Smyth; Charles L. Campbell

doi:10.1160/TH08-12-0782

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2009; 101(02): 217-219
DOI: 10.1160/TH08-12-0782

Editorial Focus

Schattauer GmbH

Platelet function analysis: At the edge of meaning

Julie H. Oestreich

¹Department of Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky, USA

,

Susan S. Smyth

²The Gill Heart Institute, University of Kentucky, Lexington, Kentucky, USA

,

Charles L. Campbell

²The Gill Heart Institute, University of Kentucky, Lexington, Kentucky, USA

› Author Affiliations

Abstract

Full Text

References

References
1 Muller I, Besta F, Schulz C. et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003; 89: 783-787.
2 Matetzky S, Shenkman B, Guetta V. et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-3175.
3 Serebruany V, Pokov I, Kuliczkowski W. et al. Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease. Thromb Haemost 2008; 100: 76-82.
4 Siller-Matula J, Schror K, Wojta J. et al. Thienopyri-dines in cardiovascular disease: Focus on clopidogrel resistance. Thromb Haemost 2007; 97: 385-393.
5 De Miguel A, Ibanez B, Badimon JJ. Clinical implications of clopidogrel resistance. Thromb Haemost Aug 2008; 100: 196-203.
6 Bonello L, Camoin-Jau L, Arques S. et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008; 51: 1404-1411.
7 Brandt JT, Payne CD, Wiviott SD. et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007; 153: 66e69-16.
8 Wiviott SD, Braunwald E, McCabe CH. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
9 Smith Jr SC, Feldman TE, Hirshfeld Jr JW. et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation. 206; 113: e166-286.
10 Gremmel T, Steiner S, Seidinger D. et al. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thromb Haemost 2009; 101: 333-339.
11 Lordkipanidze M, Pharand C, Nguyen TA. et al. Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. Eur Heart J 2008; 29: 2877-2885.
12 Paniccia R, Antonucci E, Gori AM. et al. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost 2007; 5: 1839-1847.